Cancer reports (Hoboken, N.J.) · 2026
Ten-Year Outcome of a Patient With Concurrent Pelvic Myeloid Sarcoma and Underlying Chronic Myeloid Leukaemia in Chronic Phase: A Case Report and Literature Review.
СтатьяКлинический случайОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yong Kar Ying, Lim Soo How, Lau Lee Gong, Chew Lee Ping
Аннотация
BACKGROUND: Myeloid sarcoma is a rare solid tumour of immature myeloid precursors occurring in an extramedullary site. It often presents significant diagnostic and therapeutic challenges to clinical haematologists.
CASE: We describe a previously healthy patient who presented simultaneously with hyperleucocytic chronic myeloid leukaemia in chronic phase (CML-CP) and a pelvic myeloid sarcoma (MS). She failed to respond to conventional intensive chemotherapy meant for acute myeloid leukaemia but responded well to a combination of radiotherapy and tyrosine kinase inhibitor. She has remained well and in deep molecular response for the past 10 years.
CONCLUSION: We report the first case of MS in CML-CP that has achieved 10 years of long-term remission with a combination of radiotherapy and tyrosine kinase inhibitor, without allogeneic stem cell transplantation. We also reviewed the literature on CML-CP with simultaneous MS to determine the disease characteristics and treatment outcomes.
CASE: We describe a previously healthy patient who presented simultaneously with hyperleucocytic chronic myeloid leukaemia in chronic phase (CML-CP) and a pelvic myeloid sarcoma (MS). She failed to respond to conventional intensive chemotherapy meant for acute myeloid leukaemia but responded well to a combination of radiotherapy and tyrosine kinase inhibitor. She has remained well and in deep molecular response for the past 10 years.
CONCLUSION: We report the first case of MS in CML-CP that has achieved 10 years of long-term remission with a combination of radiotherapy and tyrosine kinase inhibitor, without allogeneic stem cell transplantation. We also reviewed the literature on CML-CP with simultaneous MS to determine the disease characteristics and treatment outcomes.